A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus
Publication/Presentation Date
1-1-2019
Abstract
LESSONS LEARNED: Itacitinib in combination with
BACKGROUND: Cytokine-mediated signaling via JAK/STAT is central to tumor growth, survival, and systemic inflammation, which is associated with cancer cachexia, particularly in pancreatic cancer. Because of their centrality in the pathogenesis of cancer cachexia and progression, JAK isozymes have emerged as promising therapeutic targets. Preclinical studies have demonstrated antiproliferative effects of JAK/STAT pathway inhibition in both in vitro and in vivo models of cancer, including pancreatic cancer.
METHODS: This phase Ib/II dose-optimization study assessed itacitinib, a selective JAK1 inhibitor, combined with
RESULTS: Among 55 patients in Part 1, 6 developed seven hematologic dose-limiting toxicities (Cycle 1). Itacitinib 300 mg plus
CONCLUSION: Itacitinib plus chemotherapy demonstrated acceptable safety and clinical activity in patients with advanced solid tumors including pancreatic cancers. This study was terminated early (sponsor's decision) based on negative phase III results for a JAK1/2 inhibitor in previously treated advanced pancreatic cancer.
Volume
24
Issue
1
First Page
14
Last Page
14
ISSN
1549-490X
Published In/Presented At
Beatty, G. L., Shahda, S., Beck, T., Uppal, N., Cohen, S. J., Donehower, R., Gabayan, A. E., Assad, A., Switzky, J., Zhen, H., & Von Hoff, D. D. (2019). A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab-Paclitaxel and Gemcitabine in Advanced Solid Tumors. The oncologist, 24(1), 14–e10. https://doi.org/10.1634/theoncologist.2017-0665
Disciplines
Medicine and Health Sciences
PubMedID
30115734
Department(s)
Hematology-Medical Oncology Division
Document Type
Article